Prognostic analysis of allogeneic hematopoietic stem cell transplantation in treating patients with malignant hematological diseases
10.3760/cma.j.issn.1009-9921.2010.06.006
- VernacularTitle:异基因造血干细胞移植治疗恶性血液病的预后分析
- Author:
Feng NING
;
Jingwen WANG
;
Lei YANG
;
Jing CUI
;
Yu LI
;
Xin LI
;
Xiuxiu YIN
- Publication Type:Journal Article
- Keywords:
Hematological neoplasms;
Hematopoietic stem cell transplantation;
Transplantation homologus;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2010;19(6):338-340
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical related prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating malignant hematological diseases. Methods From September 1997 to August 2008,a total of 26 patients with hematological diseases were treated with allo-HSCT from HLA identical-sibling and haplo-identical donors in our hospital, including 14 patients with acute leukemias,10 with chronic myeloid leukemias,and 2 myelodysplastic syndromes. Results All patients achieved sustained full donor type engraftment. The cumulative overall survival (OS) was 63.9 %,and cumulative disease free survival (DFS) was 62.6 %. Fifteen patients had graft-versus-host disease (GVHD) (57.7 %),including 8 acute GVHD(aGVHD) (30.8 %) (grade Ⅲ-Ⅳ aGVHD was 15.4 %) and 7 chronic GVHD. GVHD between HLA identical-sibling and haplo-identical donors was different and there was statistic difference between the two groups (P=0.014). 4 patients relapsed,7 patients died. The univariate analysis showed OS were correlated with grade Ⅳ aGVHD (P=0.05) and CMV infection (P=0.027). Conclusion Allo-HSCT is effective for the cure of patients with malignant hematological diseases. The key to improve the efficacy of HSCT is to reduce the incidence of transplant-related complications,especially GVHD and infection.
